44 research outputs found
A potential prognostic marker in primitive lung neuroendocrine tumor: A case report.
Background: The diagnosis and monitoring of primitive lung neuroendocrine tumors (lung pNETs) are usually performed by the measurement of serum chromogranin A (CgA) and urinary 5-hydroxyindolacetic acid (5-HIAA) levels. However, imaging techniques are necessary due to the poor diagnostic efficiency of the laboratory tests. Methods: A total-body computed tomography and bone scintigraphy scans showed multiple hepatic and bone metastases of a 55-year-old man affected by well-differentiated lung pNETs without severe initial symptoms. After diagnosis, he started therapy and was monitored with serum, urinary markers, and imaging techniques. Results: During follow-up, the urinary 5-HIAA levels did not significantly increase, while serum CgA and urinary para-hydroxyphenylacetic acid (pHPAA) levels (urinary organic acid physiologically present in the urines of healthy subjects) showed significant increases related to worsening clinical condition. Conclusions: The early increase in urinary pHPAA levels—usually not dosed in pNET patient monitoring—could be a promising prognostic marker
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
Renal cell carcinoma (RCC) represents the main renal tumors and are highly metastatic. Sunitinib, a recently-approved, multi-targeted Tyrosine Kinases Inhibitor (TKi), prolongs survival in patients with metastatic renal cell carcinoma and gastrointestinal stromal tumors, however a dose related cardiotoxicity was well described. Polydatin (3,4',5-trihydroxystilbene-3-beta-d-glucoside) is a monocrystalline compound isolated from Polygonum cuspidatum with consolidated anti-oxidant and anti-inflammatory properties, however no studies investigated on its putative cardioprotective and chemosensitizing properties during incubation with sunitinib. We investigated on the effects of polydatin on the oxidative stress, NLRP3 inflammasome and Myd88 expression, highlighting on the production of cytokines and chemokines (IL-1 beta, IL-6, IL-8, CXCL-12 and TGF-beta) during treatment with sunitinib. Exposure of cardiomyocytes and cardiomyoblasts (AC-16 and H9C2 cell lines) and human renal adenocarcinoma cells (769-P and A498) to polydatin combined to plasma-relevant concentrations of sunitinib reduces significantly iROS, MDA and LTB4 compared to only sunitinib-treated cells (P<0.001). In renal cancer cells and cardiomyocytes polydatin reduces expression of pro-inflammatory cytokines and chemokines involved in myocardial damages and chemoresistance and down-regulates the signaling pathway of NLRP3 inflammasome, MyD88 and NF-kappa B. Data of the present study, although in vitro, indicate that polydatin, besides reducing oxidative stress, reduces key chemokines involved in cancer cell survival, chemoresistance and cardiac damages of sunitinib through downregulation of NLRP3-MyD88 pathway, applying as a potential nutraceutical agent in preclinical studies of preventive cardio-oncology
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy
Objectives. Serum cystatin C seems to be an accurate marker of glomerular filtration rate (GFR) compared to serum creatinine. The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal failure in cancer patients who received platinum based chemotherapy. Design and Methods. Serum creatinine, serum cystatin C concentrations, and GFR were determined simultaneously in 52 cancer patients received carboplatin-based or cisplatin-based chemotherapy. Serum creatinine was assayed on Cobas C6000-Roche, serum cystatin C assay was performed on AIA 360-Tosoh, and GFR was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations. Results. In the overall series, for the prediction of a fall of GFR < 80 mL/min/1.73 m2, the AUC of the ROC curve for cystatin C was 0,667 and the best threshold was 1.135 mg/L (sensitivity 90.5%, specificity 61.1%). For a GFR fall < 60 mL/min/1.73 m2, the AUC of ROC curve for cystatin C was 74.3% and the best threshold was 1.415 mg/L (sensitivity 66.7%, specificity 73.2%). Conclusions. Baseline cystatin C values were not able to predict renal failure during subsequent treatment. In conclusion, serum cystatin C is not a reliable early marker to efficiently predict renal failure in patients receiving chemotherapy
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Background: Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit tumor growth, suggesting a potential role in melanoma treatment.
Methods: A human melanoma cell line with the B-RAF (V600E) mutation (A375mel) was exposed to B-RAF inhibitor (GSK2118436), MEK inhibitor (GSK1120212) and AurkA inhibitor (MLN8054) as single agents or in various combinations (BRAF plus AurkA inhibitor, MEK plus AurkA inhibitor or triple combination BRAF plus MEK plus AurkA inhibitor). Cell proliferation was assessed using xCELLigence technology. Total protein extracts were examined for p53 and c-Myc protein expression by Western blot analysis. Drug anti-tumor effects were further assessed using a 3D-human melanoma skin reconstruction model, in which tissues were incubated with serum-free medium containing control, B-RAF plus MEK inhibitor, MEK plus AurkA inhibitor or the triple combination.
Results: AurkA inhibitor plus B-RAF inhibitor, AurkA inhibitor plus MEK inhibitor or triple combination had a markedly greater anti-proliferative effect on A375 (BRAFV600E) melanoma cells than single agents. In the 3D human skin model, the triple combination had a greater anti-tumor effect at the epidermal/dermal junction than control or either double combination. However, S-100 and Ki-67 positively stained spindle-shaped cells were detected in the dermal stratum, suggesting the presence of alive and proliferating melanoma cells.
Conclusions: These findings provide new prospects for melanoma research, including combined B-RAF/AurkA inhibition for B-RAF mutated melanomas and MEK/AurkA inhibitor combination for patients without B-RAF mutations. Moreover, for the first time, we have shown that a B-RAF, MEK and AurkA inhibitor triple drug combination offers increased efficacy against melanoma cell growth and might be considered as a potential treatment strategy for enhancing clinical response in melanoma. However, although this triple drug combination was more effective at the epidermal/dermal junction, the suggested presence of alive and proliferating melanoma cells in the dermal stratum could result in drug resistance and disease recurrence. Molecular characterization of these dermal cells may be critical for the development of novel therapeutic strategies
SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system
Since the first complete genome sequencing of SARS-CoV-2 in December 2019, more than 550,000 genomes have been submitted into the GISAID database. Sequencing of the SARS-CoV-2 genome might allow identification of variants with increased contagiousness, different clinical patterns and/or different response to vaccines. A highly automated next generation sequencing (NGS)-based method might facilitate an active genomic surveillance of the virus
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial
Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes. The aim of this study was to evaluate the inositol and alpha lipoic acid combination effectiveness on metabolic syndrome features in postmenopausal women at risk of breast cancer
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can individually increase the risk of specific breast cancer subtype
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology
The aim of the present study was to assess the estimated "per patient" total cost for a single Oncologic Italian Cancer Center participating in a multicenter clinical trial with new anticancer biological agents using the activity-based costing (ABC) methodology
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study
Background: Previous studies suggested that obesity and diabetes were correlated
with breast cancer outcome. The aim of the present study was to investigate the
prognostic effect of obesity and diabetes on the outcome of early breast cancer patients.
Materials and Methods: Overall, 841 early breast cancer patients were
prospectively enrolled between January 2009 and December 2013. Study population
was divided into four groups: (1) patients without obesity or diabetes; (2) patients
with only diabetes; (3) patients with only obesity; and (4) patients with both diabetes
and obesity. Categorical variables were analyzed by the chi-square test and survival
data by the log-rank test.
Results: At diagnosis, obese and diabetic patients were more likely to be older
(p < 0.0001) and post-menopausal (p < 0.0001) and to have a tumor larger than 2 cm
(p < 0.0001) than patients in groups 1–3. At univariate analyses, obese and diabetic
patients had a worse disease-free survival (p = 0.01) and overall survival (p = 0.001)
than did patients without obesity and diabetes. At multivariate analyses, the
co-presence of obesity and diabetes was an independent prognostic factor for diseasefree
survival (hazard ratio=2.62, 95% CI 1.23–5.60) but not for overall survival.
Conclusions: At diagnosis, patients with obesity and diabetes were older, had
larger tumors and a worse outcome compared to patients without obesity or diabetes.
These data suggest that metabolic health influences the prognosis of patients affected
by early breast cance
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a
devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus
cetuximab (CX) is one of the standard first-line treatments in this disease. However, this
therapeutic regimen is often associated with high toxicity and resistance, suggesting that
new combinatorial strategies are needed to improve its therapeutic index. In our study,
we evaluated the antitumor effects of valproic acid (VPA), a well-known antiepileptic
agent with histone deacetylase inhibitory activity, in combination with CDDP/CX doublet
in head and neck squamous cell carcinoma (HNSCC) models. We demonstrated, in
HNSCC cell lines, but not in normal human fibroblasts, that simultaneous exposure to
equitoxic doses of VPA plus CDDP/CX resulted in a clear synergistic antiproliferative and
pro-apoptotic effects. The synergistic antitumor effect was confirmed in four different
3D-self-assembled spheroid models, suggesting the ability of the combined approach
to affect also the cancer stem cells compartment. Mechanistically, VPA enhanced
DNA damage in combination treatment by reducing the mRNA expression of ERCC
Excision Repair 1, a critical player in DNA repair, and by increasing CDDP intracellular
concentration via upregulation at transcriptional level of CDDP influx channel copper
transporter 1 and downregulation of the ATPAse ATP7B involved in CDDP-export.
Valproic acid also induced a dose-dependent downregulation of epidermal growth factor
receptor (EGFR) expression and of MAPK and AKT downstream signaling pathways
and prevent CDDP- and/or CX-induced EGFR nuclear translocation, a well-known
mechanism of resistance to chemotherapy. Indeed, VPA impaired the transcription
of genes induced by non-canonical activity of nuclear EGFR, such as cyclin D1 and thymidylate synthase. Finally, we confirmed the synergistic antitumor effect also
in vivo in both heterotopic and orthotopic models, demonstrating that the combined
treatment completely blocked HNSCC xenograft tumors growth in nude mice. Overall,
the introduction of a safe and generic drug such as VPA into the conventional treatment
for R/M HNSCC represents an innovative and feasible antitumor strategy that warrants
further clinical evaluation. A phase II clinical trial exploring the combination of VPA and
CDDP/CX in R/M HNSCC patients is currently ongoing in our institute